POS1340 MULTICENTER STUDY OF 71 PATIENTS WITH REFRACTORY UVEITIS RELATED TO IMMUNE-MEDIATED INFLAMMATORY DISEASES ON CERTOLIZUMAB PEGOL TREATMENT

Background: Prognosis of non-infectious refractory uveitis has improved markedly with biologic therapy (BT) (1-5 ). Most data are monoclonal anti-TNF drugs, especially Adalimumab (ADA) and Infliximab (IFX). However, there is not enough evidence for the use Certolizumab Pegol (CZP). Objectives: To evaluate efficacy safety CZP in secondary to Immune-Mediated Inflammatory Diseases (IMID). Methods: Multicenter study 71 patients due IMID glucocorticoids conventional immunosuppressants. Efficacy was assessed following ocular parameters: best corrected visual acuity (BCVA), anterior chamber cells, vitritis, macular thickness presence retinal vasculitis. These outcomes were compared between baseline, 1st week, 6th month, 2nd year. Statistical analysis performed IBM SPSS Statistics v.23. Results: patients/100 affected eyes (29 men/42 women) mean age 40.0±11.3 years studied. Underlying IMIDs were: spondyloarthritis (n=38), Behçet (10), psoriatic arthritis (8), Crohn disease (3), sarcoidosis (2), JIA (1), reactive rheumatoid relapsing polychondritis TINU pars planitis Birdshot (1) idiopathic (3). Uveitis pattern (n=55), posterior (6), panuveitis (6) intermediate (4). Prior CZP, had received: methotrexate (37), sulfasalazine (26), azathioprine (14), cyclosporine leflunomide mycophenolate mofetil (3) cyclophosphamide (1). Previous BT administered 48 (67.6%) patients, a 1.4±1.3 drugs per patient as follows: ADA (n=56), IFX (27), golimumab tocilizumab (5) etanercept Pregnancy reason prescribing 19 patients. monotherapy (n=39) or combined immunosuppressants (n=32). After follow-up 27.1±21.1 months, most variables showed rapid significantly improvement (Table 1). A decrease median number [IQR] flares before after (3 [1-4] vs. 0 [0-1], p<0.001) observed. discontinued 15 remission (n=2), insufficient response (2) incomplete extraocular manifestations (11). No serious adverse events reported. Conclusion: seems be effective safe IMID. References: [1]Martín-Varillas JL, et al. Ophthalmology 2018; 125:1444-1451. doi: 10.1016/j.ophtha.2018.02.020. [2]Atienza-Mateo B, Arthritis Rheumatol 2019; 71:2081-2089. 10.1002/art.41026. [3]Santos-Gómez M, Clin Exp 2016; 34(6 Suppl 102):S34-S40. PMID: 27054359 [4]Vegas-Revenga N, Am J Ophthalmol 200:85-94. 10.1016/j.ajo.2018.12.019 [5]Calvo-Río V, Rheumatol. 2014; 32 (4 84):S54-7. 25005576 Table 1. Baseline 1 st week Month 6 th year 2 nd BCVA (mean±SD) 0.68±0.27 0.72±0.27* 0.79±0.25* 0.84±0.24* 0.85±0.25* 0.87±0.22* Improvement AC Cells, n (%) Patients cells at baseline (n=48 ) - 21 (43.7) 30 (62.5)* 41 (85.4)* (100)* Vitritis, vitritis (n=13 3 (23.1) 8 (61.5)* 11 (84.6)* 13 OCT (µ 292.5±47.7 294±47.4 286.7±41.9* 274.7±38.7* 272.8±38.9* 266.31±36.2* Choroiditis; eyes, n, (4.2) (2.8) (1.4) (0) Retinal Vasculitis; *p<0.001 Disclosure Interests: None declared